Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

  • There is currently no data for ROQ

Holding(s) in Company

22 Mar 2022 08:08

RNS Number : 5766F
Roquefort Therapeutics PLC
22 March 2022
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Roquefort Therapeutics PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Abdelatif LACHAB

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21 March 2022

6. Date on which issuer notified (DD/MM/YYYY):

22 March 2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.00

10.00

7,200,000

Position of previous notification (if

applicable)

9.04

9.04

6,500,000

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

7,200,000

10.00%

SUBTOTAL 8. A

7,200,000

10.00%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

London

Date of completion

22 March 2022

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUURWRUSUOURR
Date   Source Headline
26th Mar 20261:00 pmRNS-RInvestor Presentation
26th Mar 202612:08 pmRNSResult of General Meeting
25th Mar 20267:00 amRNSLyramid SPA & MK Cell License Update
2nd Mar 20268:00 amRNSSchedule One - Roquefort Therapeutics PLC
2nd Mar 20267:00 amRNSProposed Acquisition and Fundraise of £8.5 million
25th Feb 20267:00 amRNSTransaction Update & Notice of Intention to Delist
15th Jan 20267:00 amRNS-RResearch Note Published
12th Dec 20257:00 amRNSClinical Trial & License Agreement Update
9th Dec 20257:00 amRNSConversion of CLNs
1st Dec 202510:35 amRNSEx-Entitlement Date - Unlisted RNV Shares
1st Dec 20257:00 amRNSDetermination of Record Date and Entitlement
25th Nov 20257:00 amRNSHolding(s) in Company
24th Nov 20257:00 amRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSExecuted License Agreement & Transaction Update
3rd Nov 20257:00 amRNSMK Cell Out-License & Lyramid SPA Update
16th Oct 20257:00 amRNSFundraise & Transaction Update
30th Sep 20257:00 amRNSInterim Results to 30 June 2025
24th Sep 20257:00 amRNS-RInvestor Presentation via Engage Investor
8th Sep 20257:00 amRNSProposed Acquisition of Clinical Stage Company
28th Aug 20257:00 amRNSLyramid SPA 2nd Extension & Carve Out
7th Jul 20257:00 amRNSDirector/PDMR Shareholding
30th Jun 20257:00 amRNSDirector/PDMR Shareholding
27th Jun 20257:00 amRNSLyramid SPA Extension
26th Jun 20251:00 pmRNSResults of AGM
13th Jun 20254:00 pmRNSIssue of Equity
2nd Jun 20257:00 amRNSNotice of Annual General Meeting
23rd May 20257:00 amRNSExtension of Convertible Loan Notes
13th May 20257:00 amRNSCorporate Update
30th Apr 20257:00 amRNSAnnual Report & Financial Statements - 31 Dec 2024
14th Mar 20257:00 amRNSPrivate Placing and Conversion of CLNs
10th Mar 20257:30 amRNSBoard Changes
10th Mar 20257:00 amRNSProposed Sale of Oncogeni Ltd
4th Mar 20257:00 amRNSUpdate on Sale of Lyramid
4th Feb 202510:58 amRNSDirector/PDMR Shareholding
3rd Feb 20257:00 amRNSShare Purchase Agreement Signed - Sale of Lyramid
2nd Jan 20257:00 amRNSProposed Sale of Midkine Portfolio
4th Dec 20244:00 pmRNSDirector Share Distribution
7th Nov 20247:00 amRNSConversion of Convertible Loan Notes
27th Sep 20247:00 amRNSInterim Results to 30 June 2024
23rd Sep 20247:00 amRNSGrant of Japan MK Cell Patent
19th Sep 20247:00 amRNSSTAT-6 siRNA Demonstrates Efficacy in Immunology
2nd Sep 20247:00 amRNSGrant of MK Cell Patent & Licencing Update
27th Jun 202412:46 pmRNSResults of AGM
20th Jun 20247:00 amRNSAppointment of Broker
4th Jun 20247:00 amRNSNotice of Annual General Meeting
23rd May 20247:05 amRNSIssue of Convertible Loan Notes & Board Changes
23rd May 20247:00 amRNSMidkine Antibody Licencing Deal
26th Apr 20247:00 amRNSAnnual Report & Financial Statements - 31 Dec 2023
5th Apr 20247:00 amRNSResponse to Share Price Movement
11th Mar 20247:00 amRNSPositive Results: Midkine mRNA and STAT-6 siRNA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.